Qualigen Therapeutics (QLGN) Projected to Post Quarterly Earnings on Tuesday

Qualigen Therapeutics (NASDAQ:QLGN) is expected to post its results after the market closes on Tuesday, August 18th. Analysts expect the company to announce earnings of ($70.00) per share and revenue of $1.20 million for the quarter.

Qualigen Therapeutics Stock Down 0.4%

Shares of Qualigen Therapeutics stock opened at $0.82 on Tuesday. Qualigen Therapeutics has a 52 week low of $1.61 and a 52 week high of $8.81. The firm’s 50 day moving average is $1.06 and its two-hundred day moving average is $1.27. The firm has a market capitalization of $1.39 million, a P/E ratio of -0.11 and a beta of 0.24.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.